ArticleBMC urology2025
The relationship between the a body shape index and benign prostatic hyperplasia in middle-aged and elderly adults: a nationwide cohort study.
Article in BMC urology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThis study investigates the association between A Body Shape Index (ABSI) and risk of benign prostatic hyperplasia (BPH) in middle-aged and older men.
methodsData were obtained from the China Health and Retirement Longitudinal Study (CHARLS), including 3,223 men aged ≥ 45 years. ABSI was calculated from waist circumference, BMI, and height. Logistic regression and restricted cubic spline models were used to assess the association and potential nonlinear relationship between ABSI and incident BPH.
resultsDuring 4 years of follow-up, 260 new BPH cases were identified. A nonlinear association was observed: ABSI was significantly associated with increased BPH risk within a moderate range (7.420–8.916), but not at lower or higher ABSI levels (OR = 1.532, 95% CI: 1.015–2.314, p = 0.042).
conclusionABSI was associated with BPH risk in a nonlinear pattern. These findings suggest that ABSI may serve as a potential risk indicator, although further research is needed. Limitations include reliance on self-reported BPH diagnosis and lack of biomarker data.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.